Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02027155 · ClinicalTrials.gov registry record · Phase 1
Phase I Rising-dose Study to Assess Tolerability, Safety, Pharmacokinetics, Pharmacodynamics of AR09
A Phase 1 study, sponsored by Arbor Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT02027155 is a Phase 1 study that was terminated before completion, run by Arbor Pharmaceuticals. The registered enrollment target is 17 participants.
The verdict
NCT02027155, a Phase 1 study, was terminated before completion, sponsored by Arbor Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This will be a randomized, double-blind, placebo-controlled, rising-dose study of single IV doses of AR09 in healthy subjects. Each infusion will occur over 10 minutes.
Interventions
- DRUG placebo
- DRUG AR09 solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02027155
The ClinicalTrials.gov registry entry for NCT02027155 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arbor Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02027155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02027155 about?
NCT02027155 is a clinical study titled "Phase I Rising-dose Study to Assess Tolerability, Safety, Pharmacokinetics, Pharmacodynamics of AR09". This will be a randomized, double-blind, placebo-controlled, rising-dose study of single IV doses of AR09 in healthy subjects. Each infusion will occur over 10 minutes.
What is the current status of trial NCT02027155?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2013-12. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02027155?
The interventions under investigation include: placebo (DRUG), AR09 solution (DRUG).
Who is sponsoring clinical trial NCT02027155?
This trial is sponsored by Arbor Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.